EcoDrugPlus

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSACLG00000015251
Gene Symbol: PRKDC
1 Cross references
187 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSACLG00000022322
Gene Symbol: PPP3CA
3 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSACLG00000012512
Gene Symbol: PTK2
3 Cross references
241 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSACLG00000012333
Gene Symbol: PTK2B
3 Cross references
196 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSACLG00000024636
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSACLG00000008770
Gene Symbol: PTPRB
2 Cross references
193 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSACLG00000021170
Gene Symbol: PTPRB
2 Cross references
201 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSACLG00000017545
Gene Symbol: LOC113013184
3 Cross references
198 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSACLG00000025679
Gene Symbol: P2RX7
3 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSACLG00000014483
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSACLG00000022605
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSACLG00000019656
Gene Symbol: P2RY4
4 Cross references
168 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).